These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8541113)

  • 1. TP53 mutations and abnormal p53 protein staining in breast carcinomas related to prognosis.
    Thorlacius S; Thorgilsson B; Björnsson J; Tryggvadottir L; Börresen AL; Ogmundsdottir HM; Eyfjörd JE
    Eur J Cancer; 1995 Oct; 31A(11):1856-61. PubMed ID: 8541113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic instability and poor prognosis associated with abnormal TP53 in breast carcinomas. Molecular and immunohistochemical analysis.
    Valgardsdottir R; Tryggvadottir L; Steinarsdottir M; Olafsdottir K; Jonasdottir S; Jonasson JG; Ogmundsdottir HM; Eyfjörd JE
    APMIS; 1997 Feb; 105(2):121-30. PubMed ID: 9113074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas.
    Helland A; Holm R; Kristensen G; Kaern J; Karlsen F; Trope C; Nesland JM; Børresen AL
    J Pathol; 1993 Oct; 171(2):105-14. PubMed ID: 8283348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material.
    Gretarsdottir S; Tryggvadottir L; Jonasson JG; Sigurdsson H; Olafsdottir K; Agnarsson BA; Ogmundsdottir H; Eyfjörd JE
    Br J Cancer; 1996 Aug; 74(4):555-61. PubMed ID: 8761369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TP53 abnormalities and genetic instability in breast cancer.
    Eyfjörd JE; Thorlacius S; Valgardsdottir R; Gretarsdottir S; Steinarsdottir M; Anamthawat-Jonsson K
    Acta Oncol; 1995; 34(5):663-7. PubMed ID: 7546836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
    Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
    Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
    Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
    Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer.
    Bouzourene H; Gervaz P; Cerottini JP; Benhattar J; Chaubert P; Saraga E; Pampallona S; Bosman FT; Givel JC
    Eur J Cancer; 2000 May; 36(8):1008-15. PubMed ID: 10885605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients.
    Alsner J; Jensen V; Kyndi M; Offersen BV; Vu P; Børresen-Dale AL; Overgaard J
    Acta Oncol; 2008; 47(4):600-7. PubMed ID: 18465328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for TP53 mutations in patients and tumours from 109 Swedish breast cancer families.
    Zelada-Hedman M; Børresen-Dale AL; Claro A; Chen J; Skoog L; Lindblom A
    Br J Cancer; 1997; 75(8):1201-4. PubMed ID: 9099970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TP53 gene mutations and protein accumulation in primary vaginal carcinomas.
    Skomedal H; Kristensen G; Helland A; Nesland JM; Kooi S; Børresen AL; Holm R
    Br J Cancer; 1995 Jul; 72(1):129-33. PubMed ID: 7599041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry.
    Nenutil R; Smardova J; Pavlova S; Hanzelkova Z; Muller P; Fabian P; Hrstka R; Janotova P; Radina M; Lane DP; Coates PJ; Vojtesek B
    J Pathol; 2005 Nov; 207(3):251-9. PubMed ID: 16161005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumours and stage I carcinomas.
    Skomedal H; Kristensen GB; Abeler VM; Børresen-Dale AL; Tropé C; Holm R
    J Pathol; 1997 Feb; 181(2):158-65. PubMed ID: 9120719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of TP53 alterations in breast carcinoma.
    Andersen TI; Holm R; Nesland JM; Heimdal KR; Ottestad L; Børresen AL
    Br J Cancer; 1993 Sep; 68(3):540-8. PubMed ID: 8102535
    [TBL] [Abstract][Full Text] [Related]  

  • 15. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.
    Schmitt FC; Soares R; Cirnes L; Seruca R
    Pathol Res Pract; 1998; 194(12):815-9. PubMed ID: 9894246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53 mutation in a series of epithelial ovarian cancers from the U.K., and its prognostic significance.
    Sheridan E; Silcocks P; Smith J; Hancock BW; Goyns MH
    Eur J Cancer; 1994; 30A(11):1701-4. PubMed ID: 7833147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of p53 nuclear immunostaining is not indicative of absence of TP53 gene mutations in colorectal adenocarcinomas.
    Colomer A; Erill N; Verdú M; Roman R; Vidal A; Cordon-Cardo C; Puig X
    Appl Immunohistochem Mol Morphol; 2003 Jun; 11(2):130-7. PubMed ID: 12777996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations in residues of TP53 that directly contact DNA predict poor outcome in human primary breast cancer.
    Berns EM; van Staveren IL; Look MP; Smid M; Klijn JG; Foekens JA
    Br J Cancer; 1998 Apr; 77(7):1130-6. PubMed ID: 9569050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between p53 mutations and antibody staining in breast carcinoma.
    Dunn JM; Hastrich DJ; Newcomb P; Webb JC; Maitland NJ; Farndon JR
    Br J Surg; 1993 Nov; 80(11):1410-2. PubMed ID: 8252351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations of the TP53 gene as a potential prognostic marker in breast carcinomas. Advantages of using constant denaturant gel electrophoresis in mutation detection.
    Andersen TI; Børresen AL
    Diagn Mol Pathol; 1995 Sep; 4(3):203-11. PubMed ID: 7493140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.